People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Three stocks with yields that are less than 2% but that have been increasing their dividends at high rates in recent years ...

Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

President Donald Trump said he planned to implement a 50% duty on copper imports as part of a set of looming sectoral tariffs ...